Chicago-based Rosalind Franklin University of Medicine and Science (RFU) and Aptinyx, a US-based clinical-stage biopharmaceutical company, have entered into a research collaboration to support the development of new therapeutics for brain and central nervous system disorders, it was reported on Wednesday.
RFU's Brain Science Institute aims to identify and solve fundamental aspects of brain function and development and utilise those findings to understand the mechanisms of brain diseases. Under a recently executed research agreement, investigators within the institute will partner with Evanston-based Aptinyx, which is developing novel therapies for neurologic disorders including chronic pain, post-traumatic stress disorder and cognitive impairment.
Amiel Rosenkranz, PhD, director of the Brain Science Institute, said, 'This is an exciting opportunity for neuroscientists at RFU to contribute to the advancement of novel treatments for difficult-to-treat disorders. We are grateful to be working with Aptinyx on their promising therapeutics.'
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Lipocine doses first cohort in LPCN 1154 study
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates